Medicine affordability and access in India: lessons from generic–branded price variation under the Jan Aushadhi Scheme
The Jan Aushadhi Scheme has made measurable progress in improving medicine affordability, but inequities in access, persistent price variation, and limited uptake constrain its full potential. Strengthening regulatory oversight, improving geographic distribution, and addressing physician and patient perceptions of generics are essential to maximize policy impact. Future research should apply quasi-experimental methods and integrate patient perception data to better capture the affordability-access-adherence pathway.
Authors
- Deepak Kumar Behera (ORCID: https://orcid.org/0000-0001-6539-4280)
- Dil Bahadur Rahut (ORCID: https://orcid.org/0000-0002-7505-5271)
- Shaik Husna Tasneem
- Mehnaaz Dhanal Mehboobali
- Ambigai Rajendhran
Institutions
- RMIT Vietnam (VN)
- Manipal Academy of Higher Education (IN)
- Flinders University (AU)
- Asian Development Bank Institute (JP)
- Ho Chi Minh City International University (VN)
- Flinders Medical Centre (AU)
- Adelaide Institute for Sleep Health (AU)
- Cytel (United States) (US)
Publication Details
- Journal
- Frontiers in Public Health
- Published
- 2025-12-05
- DOI
- https://doi.org/10.3389/fpubh.2025.1629835
- Citations
- 1
- Primary Topic
- Pharmaceutical Economics and Policy
- Type
- article
- Field-Weighted Citation Impact
- 3.13